MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by plexiform neurofibromas (PNFs).
• The role of microRNAs (miRs) in NF1-associated PNFs, driven by biallelic NF1 mutations in Schwann cells (SCs), remains largely unexplored.
• Understanding miR dysregulation is crucial for identifying novel therapeutic targets in NF1 PNFs.

Purpose of the Study:

• To investigate the role and potential therapeutic targeting of dysregulated miRs in NF1 plexiform neurofibromas.
• To identify specific miRs involved in the proliferation and tumorigenesis of NF1-associated SCs.
• To evaluate the therapeutic efficacy of targeting miR-155 in preclinical models of NF1 PNFs.

Main Methods:

• Comparative miR microarray analysis of normal and PNF SCs, followed by qRT-PCR validation in mouse models.
• Assessing the impact of miR-155 overexpression and inhibition on SC proliferation and PNF-derived sphere formation in vitro.
• Evaluating the in vivo effects of global miR-155 deletion on tumor growth and survival in a mouse model.
• Investigating the therapeutic potential of anti-miR-155 nanoparticles in established PNFs.

Main Results:

• miR-155 was identified as a significantly overexpressed miR in NF1 PNFs, regulated by RAS/MAPK signaling.
• Overexpression of miR-155 enhanced proliferation of Nf1-/- SCs, while its inhibition reduced PNF-derived sphere formation.
• Global deletion of miR-155 in mice led to decreased tumor number and volume, improving survival.
• Anti-miR-155 nanoparticle treatment showed marginal effects on established PNFs.

Conclusions:

• miR-155 plays a functional role in NF1 PNF growth and SC proliferation.
• Targeting miRs, specifically miR-155, presents a feasible and potentially novel therapeutic strategy for NF1.
• Further research is warranted to optimize anti-miR therapies for NF1 PNFs.